Earnings ·
Novavax reports Q3 revenue of $68M, raises full-year adjusted total revenue guidance to $400M
NVAXNovavax Inc
Novavax reported third-quarter 2026 total revenue of $68 million, a 3% decrease from the prior year period. The company raised its full-year 2026 Non-GAAP Adjusted Total Revenue guidance by $145 million to a midpoint of $400 million and improved GAAP Combined R&D and SG&A expense guidance by $5 million at mid-point. In October, Novavax received a $125 million milestone payment from Sanofi upon the initiation of a Phase 3 influenza-COVID-19 combination vaccine trial in Europe. The company also confirmed Sanofi's intent to initiate a U.S. Phase 3 trial for the same combination vaccine in 2027. Novavax operates as a biotechnology company focused on developing vaccines and adjuvant technologies.